Impact of P53 and SIRT1 in Type 2 Diabetes

Phase 3

Recruiting

• Conditions: DM
• Interventions: Other: life style; Drug: Metformin; Drug: Nigetella salivata

• Registration Number: NCT03925714
• Lead Sponsor: Sherief Abd-Elsalam

Brief Summary

Investigating the impact of p53 and SIRT1 in the development of type 2 DM

Detailed Description

Investigating the impact of p53 and SIRT1 in the development of type 2 DM through the treatment of prediabetic individuals by either nigetella salivata or Metformin

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Status Verified: 2019-04
• Study Start: 2019-04-01
• Study First Submitted: 2019-04-22
• Study First Submitted QC: 2019-04-22
• Last Update Submitted: 2019-04-22
• Study First Posted: 2019-04-24
• Last Update Posted: 2019-04-24
• Primary Completion: 2028-12
• Study Completion: 2028-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

• Prediabetic subjects.

Read More

Exclusion Criteria

• Confirmed diabetes.
• Hepatic or renal impairment.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
life style	life style	life style control only
Metformin	Metformin	Metformin 500 mg twice daily
Nigetella salivata	Nigetella salivata	NS 450 mg twice daily

Primary Outcome Measures

Name	Time	Method
Number of patients with improved insulin resistance	6 months	Number of patients showing improved insulin resistance

Trial Locations

Locations (1)

Sherief Abd-Elsalam; 🇪🇬 Cairo, Egypt